2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52) - a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacyin vivo

5-lipoxygenase as an endogenous modulator of amyloid beta formation in vivo

(2010) Jin Chu et al.   ANNALS OF NEUROLOGY

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation

(2010) Daniel S. Lorrain et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

5-Lipoxygenase inhibitors: a review of recent developments and patents

(2010) Carlo Pergola et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations

(2009) Svenja D. Steinbrink et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo

(2009) Christian Feißt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis

(2009) Magnus Back   CURRENT PHARMACEUTICAL DESIGN

Novel and Potent Inhibitors of 5-Lipoxygenase Product Synthesis Based on the Structure of Pirinixic Acid

(2008) Oliver Werz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pirinixic Acid Derivatives as Novel Dual Inhibitors of Microsomal Prostaglandin E2Synthase-1 and 5-Lipoxygenase

(2008) Andreas Koeberle et al.   JOURNAL OF MEDICINAL CHEMISTRY

ERK-mediated regulation of leukotriene biosynthesis by androgens: A molecular basis for gender differences in inflammation and asthma

(2008) C. Pergola et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA